SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934



        Date of Report (Date of earliest event reported): April 28, 2003



                           WRIGHT MEDICAL GROUP, INC.
             (Exact name of registrant as specified in its charter)


       Delaware                      000-32883                 13-4088127
(State or other jurisdiction        (Commission               (IRS Employer
   of  incorporation)                File Number)         Identification Number)


   5677 Airline Road, Arlington, Tennessee                    38002
  (Address of principal executive offices)                  (Zip Code)


       Registrant's telephone number, including area code: (901) 867-9971

--------------------------------------------------------------------------------
<PAGE>
Item 7.    Financial Statements and Exhibits

           (c)    Exhibits

                  The following exhibit is included as part of this report:

     Exhibit
     Number                                 Description
-----------------       --------------------------------------------------------

       99               Press release issued by Wright Medical Group, Inc. on
                        April 28, 2003.

Item 9.    Regulation FD Disclosure

On April 28, 2003,  Wright Medical Group,  Inc. (the  "Company")  issued a press
release  announcing  its  consolidated  financial  results for the quarter ended
March 31, 2003.  A copy of the press  release is furnished as Exhibit 99 to this
report. The information  contained in this report,  including the press release,
is furnished pursuant to Item 12 under Item 9 of Form 8-K in accordance with the
interim guidance  provided by the Securities and Exchange Commission in Release
No. 34-47583.

<PAGE>


                                    SIGNATURE


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

       Date:  April 28, 2003

                                  WRIGHT MEDICAL GROUP, INC.


                                  By:/s/ F. Barry Bays
                                     -------------------------------------
                                     F. Barry Bays
                                     President and Chief Executive Officer

                                       2
<PAGE>


                                  EXHIBIT INDEX

 Exhibit Number
                                            Description
-----------------       --------------------------------------------------------

       99               Press release issued by Wright Medical Group, Inc. on
                        April 28, 2003.

<PAGE>
                                                                     Exhibit 99

                                                  FOR RELEASE 3:00 P.M. CENTRAL
                                                         MONDAY, APRIL 28, 2003
                                                      Contact: John K. Bakewell
                                                                 (901) 867-4527



                 Wright Medical Group, Inc. Reports Results for
                       First Quarter Ended March 31, 2003

 Quarter's Net Sales and Operating Income, Excluding Acquisition-related Charge,
                        are Highest in Company's History


ARLINGTON,  TN - April 28, 2003 - Wright Medical Group, Inc.  (NASDAQ:  WMGI), a
global   orthopaedic   medical  device  company   specializing  in  the  design,
manufacture and marketing of  reconstructive  joint devices and  bio-orthopaedic
materials,  today reported  record results for its first quarter ended March 31,
2003.

Net sales for the first quarter of 2003 totaled $58.6  million,  representing  a
13% increase over net sales of $51.7  million  during the first quarter of 2002.
First quarter net sales achieved a record level for any quarter in the Company's
history.  First quarter net sales  benefited from a favorable  foreign  currency
impact  totaling  approximately  $3.2  million.  First  quarter  2003  Generally
Accepted  Accounting  Principles  ("GAAP") net income,  totaled $2.0 million, or
$.06 per  diluted  share,  including  the  after-tax  effect  of a $4.6  million
in-process  research and  development  ("IPRD")  charge which,  as  anticipated,
resulted from the Company's  first quarter  acquisition of certain  ADCON(R) Gel
technology assets. Without this charge, net income for the first quarter of 2003
would have been $4.8 million, or $.14 per diluted share. First quarter 2002 GAAP
net  income  totaled  $6.9  million or $.21 per  diluted  share,  including  the
favorable after-tax effect of a $4.2 million award from a commercial arbitration
proceeding with a former business services  provider.  Excluding the arbitration
settlement  award,  the Company's net income  totaled $4.3 million,  or $.13 per
diluted share for the prior-year first quarter.

First quarter GAAP income from operations,  inclusive of the aforementioned 2003
IPRD charge and 2002 arbitration settlement award totaled $3.5 million and $10.3
million in 2003 and 2002,  respectively.  First quarter income from  operations,
exclusive  of these  items,  increased  by 31%  year-over-year,  to an  all-time
quarterly record of $8.0 million,  or 14% of sales,  during the first quarter of
2003,  from $6.1 million,  or 12% of sales,  during the first quarter of 2002. A
reconciliation  of GAAP to "as  adjusted"  results is included  in the  attached
financial tables.

F. Barry Bays,  President and Chief Executive  Officer  commented,  "We are very
pleased with our operating performance for the first quarter, which exceeded the
upper end of our outlook  ranges for both net sales and income from  operations,
excluding the impact of our IPRD charge  related to the ADCON(R) Gel  technology
acquisition.  Domestic  first  quarter net sales  results  reflect the continued
exceptional  performance of our growth-driving  bio-orthopaedics and extremities
product lines. Additionally,  within our domestic reconstructive joint business,
our knee  results  have  shown  improvement  during  the first  quarter  that is
consistent  with our  internal  goals,  while  our hip  product  line  posted an
exceptional 23% growth rate for the quarter,  reflecting  early success from the
recent launch of our LINEAGE(R) ceramic-on-ceramic hip system."

Mr. Bays continued,  "Our solid revenue performance during the quarter, combined
with continued operating leverage,  has again produced operating income results,
excluding our IPRD charge,  that surpassed our expectations.  Notably,  in every
quarter  reported since becoming a public  company,  we have met or exceeded our
performance expectations.  The first quarter of 2003 now marks eight consecutive
quarters for such  achievement.  Our outlook for the  remainder of 2003 is quite
encouraging  as  well,  due,  in  part,  to  the  continued   expansion  of  our
bio-orthopaedics  franchise  to include  additional  technology  platforms,  the
initial  success of our LINEAGE(R)  ceramic-on-ceramic  hip system,  and what is
likely to be a favorable international currency environment."
<PAGE>
                                                                   (Page 2 of 6)
Sales Review
------------

The Company  experienced global growth across all its major product lines during
the first  quarter,  with the  Company's  bio-orthopaedic  and hip product lines
posting  exceptional  growth  rates.  Specifically,  global  net  sales  of  the
Company's  bio-orthopaedic,  hip, extremity, and knee product lines increased by
25%,  24%,  11% and 2%,  respectively,  during  the first  quarter  of 2003 when
compared to the first quarter of 2002.

Domestic  sales  totaled  $35.1  million  during  the  first  quarter  of  2003,
representing  an increase of 13.5% compared to the respective  year-ago  period.
Domestically,  net sales of the Company's bio-orthopaedic,  hip, and extremities
product lines  reflected  growth of 29%, 23% and 19%,  respectively,  while knee
sales decreased by 2% as compared to the respective year-ago period.

International sales totaled $23.5 million during the first quarter of 2003,
representing an increase of 13% compared to the first quarter of 2002.

Outlook
-------

The Company has upwardly revised its previously communicated sales and operating
income targets for 2003 to reflect over-achievement experienced during the first
quarter of 2003 and an  improved  outlook  for the  remainder  of the year.  The
Company's  anticipated  net sales  targets for the full year 2003 are now in the
range  of $229  million  to $234  million,  representing  annualized  growth  of
approximately  14% to 16.5%,  with operating  income targets now totaling $28 to
$30 million,  exclusive of the Company's $4.6 million first quarter of 2003 IPRD
charge. The Company's anticipated targets for the second quarter of 2003 for net
sales are in the range of $57  million to $59  million,  with  operating  income
results  ranging from $7.2 to $7.9 million.  These targets for both the upcoming
second  quarter of 2003 and the full year of 2003 exclude the effect of possible
future acquisitions or other material future business developments.

The Company's  anticipated  targets for net sales and income from operations are
forward-looking  statements. They are subject to various risks and uncertainties
that could cause the  Company's  actual  results to differ  materially  from the
anticipated  targets.  The  anticipated  targets  are  not  predictions  of  the
Company's   actual   performance.   See   the   cautionary   information   about
forward-looking  statements in the "Safe-Harbor Statement" section of this press
release.

Conference Call
---------------

As  previously  announced,  the Company will host a conference  call starting at
3:30  p.m.  (Central  Time)  today.  To  access a  simultaneous  webcast  of the
conference call via the internet,  go to the "Corporate - Investor  Information"
section  of the  Company's  website  located  at  www.wmt.com.  A replay  of the
conference  call by telephone  will be available  starting  today and continuing
until  10:59 p.m.  (Central  Time) on May 5,  2003.  To hear this  replay,  dial
1-800-428-6051  and  enter  the  registration  number  289932.  A replay  of the
conference  call will also be  available  via the  internet  starting  today and
continuing for at least 12 months. To access a replay of the conference call via
the internet,  go to the  "Corporate - Investor  Information  - Audio  Archives"
section of the Company's website located at www.wmt.com.

The  conference  call may include a discussion of non-GAAP  financial  measures.
Reference is made to the most directly comparable GAAP financial  measures,  the
reconciliation of the differences  between the two financial  measures,  and the
other information  included in this press release or otherwise  available in the
"Corporate - Investor  Information"  section of the Company's website located at
www.wmt.com.

The conference call may include forward-looking statements. See the cautionary
information about forward-looking statements in the "Safe-Harbor Statement"
section of this press release.

<PAGE>
                                                                   (Page 3 of 6)
Non-GAAP Financial Measures
---------------------------

The Company uses non-GAAP financial  measures,  such as net income, as adjusted,
income from operations,  as adjusted, cash earnings, as adjusted and net income,
as adjusted,  per diluted  share.  The  Company's  management  believes that the
presentation of these measures provides useful  information to investors.  These
measures may assist  investors in evaluating  the Company's  operations,  period
over period. The measures exclude such items as business development  activities
including purchased in-process research and development and the financial impact
of significant  litigation,  which may be highly variable,  difficult to predict
and of a size that  could  have  substantial  impact on the  Company's  reported
results of operations for a period.  Management  uses these measures  internally
for evaluation of the  performance of the business,  including the allocation of
resources  and the  evaluation  of  results  relative  to  employee  performance
compensation targets.  Investors should consider these non-GAAP measures only as
a  supplement  to,  not as a  substitute  for or as  superior  to,  measures  of
financial performance prepared in accordance with GAAP.

Safe-Harbor Statement
---------------------
This press release may contain  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange Act of 1934, as amended.  All statements made in this press
release,   other  than  statements  of  historical  fact,  are   forward-looking
statements.  Forward-looking  statements reflect management's current knowledge,
assumptions,  beliefs,  estimates,  and  expectations  and express  management's
current views of future performance,  results, and trends. The Company wishes to
caution readers that actual results might differ materially from those described
in the forward-looking  statements.  Forward-looking statements are subject to a
number  of risks and  uncertainties,  including  the  factors  discussed  in the
Company's  filings with the  Securities and Exchange  Commission  (including the
Company's  annual  report on Form 10-K for the year ended  December  31,  2002),
which could cause the Company's  actual results to materially  differ from those
described in the forward-looking statements.  Although the Company believes that
the forward-looking  statements are accurate, there can be no assurance that any
forward-looking statement will prove to be accurate. A forward-looking statement
should not be  regarded  as a  representation  by the  Company  that the results
described therein will be achieved. The Company wishes to caution readers not to
place  undue  reliance on any  forward-looking  statement.  The  forward-looking
statements are made as of the date of this press release. The Company assumes no
obligation to update any forward-looking statement after this date.

Wright  Medical  Group,  Inc. is a global  orthopaedic  medical  device  company
specializing in the design,  manufacture and marketing of  reconstructive  joint
devices and bio-orthopaedic materials. The Company has been in business for more
than fifty years and markets its  products in over 40 countries  worldwide.  For
more information about Wright Medical, visit our website at www.wmt.com.


                               --Tables Follow--
<PAGE>

                                                                   (Page 4 of 6)

                           Wright Medical Group, Inc.
                 Consolidated Condensed Statements of Operations
                      (in thousands, except per share data)
                                   (unaudited)
                                                        Three Months Ended
                                                  ---------------------------
                                                    March 31,      March 31,
                                                      2003           2002
                                                  ------------    ----------

Net sales                                            $ 58,622      $ 51,706
Cost of sales                                          15,540        14,758
                                                  ------------    ----------
       Gross profit                                    43,082        36,948

Operating Expenses:
    Selling, general and administrative                30,305        26,955
    Research and development                            3,535         2,561
    Amortization of intangible assets                     804           853
    Stock-based expense                                   409           440
    Arbitration settlement award                            -        (4,200)
    Acquired in-process research and
    development costs                                   4,558             -
                                                  ------------    ----------
       Total operating expenses                        39,611        26,609
                                                  ------------    ----------

       Income from operations                           3,471        10,339
Interest expense, net                                     266           434
Other (income) expense, net                              (30)            16
                                                  ------------    ----------
       Income before income taxes                       3,235         9,889
Provision for income taxes                              1,234         2,970
                                                  ------------    ----------
       Net income                                    $  2,001      $  6,919
                                                  ============    ==========

Net income per common share--basic                   $    .06      $    .23
                                                  ============    ==========
Net income per common share--diluted                 $    .06      $    .21
                                                  ============    ==========
Weighted-average number of common shares
outstanding-basic                                      32,715        29,833
                                                  ============    ==========
Weighted-average number of common shares
outstanding-diluted
                                                       34,059        32,229
                                                  ============    ==========


                           Wright Medical Group, Inc.
                      Consolidated Condensed Sales Analysis
                       (dollars in thousands - unaudited)

                                                      Three Months Ended
                                         ----------------------------------
                                          March 31,   March 31,      %
                                            2003        2002       change
                                         ---------- ----------- ----------
Geographic
--------------------------
Domestic                                   $35,080    $30,914       13.5%
International                               23,542     20,792       13.2%
                                         ---------- ----------- ----------
Total net sales                            $58,622    $51,706       13.4%
                                         ========== =========== ==========
Product Line
--------------------------
Knee products                              $19,664    $19,303        1.9%
Hip products                                17,690     14,240       24.2%
Extremity products                           7,430      6,695       11.0%
Bio-orthopaedic materials                   11,409      9,162       24.5%
Other                                        2,429      2,306        5.3%
                                         ---------- ----------- ----------
Total net sales                            $58,622    $51,706       13.4%
                                         ========== =========== ==========

<PAGE>
                                                                   (Page 5 of 6)

                           Wright Medical Group, Inc.
       Reconciliation of Income from Operations to Income from Operations,
                 As Adjusted (dollars in thousands - unaudited)

                                                        Three Months Ended
                                                  ----------------------------
                                                    March 31,       March 31,
                                                      2003             2002
                                                  ------------   -------------
Income from Operations, as reported                  $  3,471        $ 10,339
Add:  Acquired in-process research and
development costs                                       4,558               -
Less:  Arbitration settlement award                         -         (4,200)
                                                  ------------   -------------
Income from Operations, as adjusted                  $  8,029         $ 6,139
                                                  ============   =============



                           Wright Medical Group, Inc.
             Reconciliation of Net Income to Net Income, As Adjusted
                       (dollars in thousands - unaudited)

                                                         Three Months Ended
                                                     --------------------------
                                                       March 31,     March 31,
                                                         2003          2002
                                                     ------------   -----------

Net income, as reported:                                  $2,001       $ 6,919
Add:  Acquired in-process research and
development costs, net of tax                              2,819             -
Less:  Arbitration settlement award, net of tax                -        (2,604)
                                                     ------------   -----------
Net income, as adjusted:                                $  4,820       $ 4,315

Net income, as adjusted, per common share--basic        $    .15       $   .14
                                                     ============   ===========
Net income, as adjusted, per common
share--diluted                                          $    .14       $   .13
                                                     ============   ===========
Weighted-average number of common shares
outstanding-basic                                         32,715        29,833
                                                     ============   ===========
Weighted-average number of common shares
outstanding-diluted                                       34,059        32,229
                                                     ============   ===========


                           Wright Medical Group, Inc.
  Reconciliation of Net Income to Cash Earnings and Cash Earnings, As Adjusted
                       (dollars in thousands - unaudited)

                                                        Three Months Ended
                                                  ------------------------------
                                                      March 31,        March 31,
                                                        2003             2002
                                                    ------------    ------------

Net income, as reported                                 $2,001         $ 6,919
Add:  Stock-based expense                                  409             440
Add:  Amortization of intangible assets                    804             853
                                                    ------------    ------------
    Cash earnings                                        3,214           8,212
Add:  Acquired in-process research and
development costs, net of tax                            2,819               -
Less:  Arbitration settlement award, net of tax              -          (2,604)
                                                    ------------    ------------
Cash earnings, as adjusted                            $  6,033         $ 5,608
                                                    ============    ============

<PAGE>
                                                                   (Page 6 of 6)
                           Wright Medical Group, Inc.
                      Consolidated Condensed Balance Sheets
                      (in thousands, except per share data)


                                                      March 31,     December 31,
                                                        2003           2002
                                                   ------------     ------------

Assets:
Current Assets:
    Cash and cash equivalents                         $ 52,841       $   51,373
    Accounts receivable, net                            44,747           39,571
    Inventories                                         58,418           55,628
    Prepaid expenses and other current assets           22,676           25,042
                                                   ------------      ----------
         Total current assets                          178,682          171,614
                                                   ------------      ----------
Property, plant and equipment, net                      59,198           59,215
Intangible assets, net                                  29,288           26,908
Other assets                                            15,943           16,446
                                                   ------------      ----------
                                                      $283,111         $274,183
                                                   ============      ==========

Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
    Accounts payable                                     $ 10,149      $   9,878
    Accrued expenses and other current liabilities         34,820         29,878
    Current portion of long-term obligations                5,778          5,676
                                                      ------------    ----------
       Total current liabilities                           50,747         45,432
                                                      ------------    ----------
Long-term obligations                                      16,321         16,586
Other liabilities                                           6,679          7,166
                                                      ------------    ----------
       Total liabilities                                   73,747         69,184
                                                      ------------    ----------

Stockholders' equity (deficit)                            209,364        204,999
                                                      ------------    ----------
                                                       $  283,111     $  274,183
                                                      ============    ==========
[{"type": "8-K", "sequence": "1", "filename": "wrightmedical8k042803.txt", "description": "CURRENT REPORT", "secsgml_size_bytes": 27065}]
{"company-data": {"conformed-name": "WRIGHT MEDICAL GROUP INC", "cik": "0001137861", "assigned-sic": "3842", "irs-number": "134088127", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-32883", "film-number": "03667032"}, "business-address": {"street1": "5677 AIRLINE ROAD", "city": "ARLINGTON", "state": "TN", "zip": "38002", "phone": "9018679971"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 28, 2003

                           WRIGHT MEDICAL GROUP, INC.
             (Exact name of registrant as specified in its charter)

       Delaware                      000-32883                 13-4088127
(State or other jurisdiction        (Commission               (IRS Employer
   of  incorporation)                File Number)         Identification Number)

   5677 Airline Road, Arlington, Tennessee                    38002
  (Address of principal executive offices)                  (Zip Code)

       Registrant's telephone number, including area code: (901) 867-9971

--------------------------------------------------------------------------------
Item 7.    Financial Statements and Exhibits

           (c)    Exhibits

                  The following exhibit is included as part of this report:

     Exhibit
     Number                                 Description
-----------------       --------------------------------------------------------

       99               Press release issued by Wright Medical Group, Inc. on
                        April 28, 2003.

Item 9.    Regulation FD Disclosure

On April 28, 2003,  Wright Medical Group,  Inc. (the  "Company")  issued a press
release  announcing  its  consolidated  financial  results for the quarter ended
March 31, 2003.  A copy of the press  release is furnished as Exhibit 99 to this
report. The information  contained in this report,  including the press release,
is furnished pursuant to Item 12 under Item 9 of Form 8-K in accordance with the
interim guidance  provided by the Securities and Exchange Commission in Release
No. 34-47583.
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

       Date:  April 28, 2003

                                  WRIGHT MEDICAL GROUP, INC.

                                  By:/s/ F. Barry Bays
                                     -------------------------------------
                                     F. Barry Bays
                                     President and Chief Executive Officer

                                       2
EXHIBIT INDEX

 Exhibit Number
                                            Description
-----------------       --------------------------------------------------------

       99               Press release issued by Wright Medical Group, Inc. on
                        April 28, 2003.
Exhibit 99

                                                  FOR RELEASE 3:00 P.M. CENTRAL
                                                         MONDAY, APRIL 28, 2003
                                                      Contact: John K. Bakewell
                                                                 (901) 867-4527

                 Wright Medical Group, Inc. Reports Results for
                       First Quarter Ended March 31, 2003

 Quarter's Net Sales and Operating Income, Excluding Acquisition-related Charge,
                        are Highest in Company's History

ARLINGTON,  TN - April 28, 2003 - Wright Medical Group, Inc.  (NASDAQ:  WMGI), a
global   orthopaedic   medical  device  company   specializing  in  the  design,
manufacture and marketing of  reconstructive  joint devices and  bio-orthopaedic
materials,  today reported  record results for its first quarter ended March 31,
2003.

Net sales for the first quarter of 2003 totaled $58.6  million,  representing  a
13% increase over net sales of $51.7  million  during the first quarter of 2002.
First quarter net sales achieved a record level for any quarter in the Company's
history.  First quarter net sales  benefited from a favorable  foreign  currency
impact  totaling  approximately  $3.2  million.  First  quarter  2003  Generally
Accepted  Accounting  Principles  ("GAAP") net income,  totaled $2.0 million, or
$.06 per  diluted  share,  including  the  after-tax  effect  of a $4.6  million
in-process  research and  development  ("IPRD")  charge which,  as  anticipated,
resulted from the Company's  first quarter  acquisition of certain  ADCON(R) Gel
technology assets. Without this charge, net income for the first quarter of 2003
would have been $4.8 million, or $.14 per diluted share. First quarter 2002 GAAP
net  income  totaled  $6.9  million or $.21 per  diluted  share,  including  the
favorable after-tax effect of a $4.2 million award from a commercial arbitration
proceeding with a former business services  provider.  Excluding the arbitration
settlement  award,  the Company's net income  totaled $4.3 million,  or $.13 per
diluted share for the prior-year first quarter.

First quarter GAAP income from operations,  inclusive of the aforementioned 2003
IPRD charge and 2002 arbitration settlement award totaled $3.5 million and $10.3
million in 2003 and 2002,  respectively.  First quarter income from  operations,
exclusive  of these  items,  increased  by 31%  year-over-year,  to an  all-time
quarterly record of $8.0 million,  or 14% of sales,  during the first quarter of
2003,  from $6.1 million,  or 12% of sales,  during the first quarter of 2002. A
reconciliation  of GAAP to "as  adjusted"  results is included  in the  attached
financial tables.

F. Barry Bays,  President and Chief Executive  Officer  commented,  "We are very
pleased with our operating performance for the first quarter, which exceeded the
upper end of our outlook  ranges for both net sales and income from  operations,
excluding the impact of our IPRD charge  related to the ADCON(R) Gel  technology
acquisition.  Domestic  first  quarter net sales  results  reflect the continued
exceptional  performance of our growth-driving  bio-orthopaedics and extremities
product lines. Additionally,  within our domestic reconstructive joint business,
our knee  results  have  shown  improvement  during  the first  quarter  that is
consistent  with our  internal  goals,  while  our hip  product  line  posted an
exceptional 23% growth rate for the quarter,  reflecting  early success from the
recent launch of our LINEAGE(R) ceramic-on-ceramic hip system."

Mr. Bays continued,  "Our solid revenue performance during the quarter, combined
with continued operating leverage,  has again produced operating income results,
excluding our IPRD charge,  that surpassed our expectations.  Notably,  in every
quarter  reported since becoming a public  company,  we have met or exceeded our
performance expectations.  The first quarter of 2003 now marks eight consecutive
quarters for such  achievement.  Our outlook for the  remainder of 2003 is quite
encouraging  as  well,  due,  in  part,  to  the  continued   expansion  of  our
bio-orthopaedics  franchise  to include  additional  technology  platforms,  the
initial  success of our LINEAGE(R)  ceramic-on-ceramic  hip system,  and what is
likely to be a favorable international currency environment."
(Page 2 of 6)
Sales Review
------------

The Company  experienced global growth across all its major product lines during
the first  quarter,  with the  Company's  bio-orthopaedic  and hip product lines
posting  exceptional  growth  rates.  Specifically,  global  net  sales  of  the
Company's  bio-orthopaedic,  hip, extremity, and knee product lines increased by
25%,  24%,  11% and 2%,  respectively,  during  the first  quarter  of 2003 when
compared to the first quarter of 2002.

Domestic  sales  totaled  $35.1  million  during  the  first  quarter  of  2003,
representing  an increase of 13.5% compared to the respective  year-ago  period.
Domestically,  net sales of the Company's bio-orthopaedic,  hip, and extremities
product lines  reflected  growth of 29%, 23% and 19%,  respectively,  while knee
sales decreased by 2% as compared to the respective year-ago period.

International sales totaled $23.5 million during the first quarter of 2003,
representing an increase of 13% compared to the first quarter of 2002.

Outlook
-------

The Company has upwardly revised its previously communicated sales and operating
income targets for 2003 to reflect over-achievement experienced during the first
quarter of 2003 and an  improved  outlook  for the  remainder  of the year.  The
Company's  anticipated  net sales  targets for the full year 2003 are now in the
range  of $229  million  to $234  million,  representing  annualized  growth  of
approximately  14% to 16.5%,  with operating  income targets now totaling $28 to
$30 million,  exclusive of the Company's $4.6 million first quarter of 2003 IPRD
charge. The Company's anticipated targets for the second quarter of 2003 for net
sales are in the range of $57  million to $59  million,  with  operating  income
results  ranging from $7.2 to $7.9 million.  These targets for both the upcoming
second  quarter of 2003 and the full year of 2003 exclude the effect of possible
future acquisitions or other material future business developments.

The Company's  anticipated  targets for net sales and income from operations are
forward-looking  statements. They are subject to various risks and uncertainties
that could cause the  Company's  actual  results to differ  materially  from the
anticipated  targets.  The  anticipated  targets  are  not  predictions  of  the
Company's   actual   performance.   See   the   cautionary   information   about
forward-looking  statements in the "Safe-Harbor Statement" section of this press
release.

Conference Call
---------------

As  previously  announced,  the Company will host a conference  call starting at
3:30  p.m.  (Central  Time)  today.  To  access a  simultaneous  webcast  of the
conference call via the internet,  go to the "Corporate - Investor  Information"
section  of the  Company's  website  located  at  www.wmt.com.  A replay  of the
conference  call by telephone  will be available  starting  today and continuing
until  10:59 p.m.  (Central  Time) on May 5,  2003.  To hear this  replay,  dial
1-800-428-6051  and  enter  the  registration  number  289932.  A replay  of the
conference  call will also be  available  via the  internet  starting  today and
continuing for at least 12 months. To access a replay of the conference call via
the internet,  go to the  "Corporate - Investor  Information  - Audio  Archives"
section of the Company's website located at www.wmt.com.

The  conference  call may include a discussion of non-GAAP  financial  measures.
Reference is made to the most directly comparable GAAP financial  measures,  the
reconciliation of the differences  between the two financial  measures,  and the
other information  included in this press release or otherwise  available in the
"Corporate - Investor  Information"  section of the Company's website located at
www.wmt.com.

The conference call may include forward-looking statements. See the cautionary
information about forward-looking statements in the "Safe-Harbor Statement"
section of this press release.
(Page 3 of 6)
Non-GAAP Financial Measures
---------------------------

The Company uses non-GAAP financial  measures,  such as net income, as adjusted,
income from operations,  as adjusted, cash earnings, as adjusted and net income,
as adjusted,  per diluted  share.  The  Company's  management  believes that the
presentation of these measures provides useful  information to investors.  These
measures may assist  investors in evaluating  the Company's  operations,  period
over period. The measures exclude such items as business development  activities
including purchased in-process research and development and the financial impact
of significant  litigation,  which may be highly variable,  difficult to predict
and of a size that  could  have  substantial  impact on the  Company's  reported
results of operations for a period.  Management  uses these measures  internally
for evaluation of the  performance of the business,  including the allocation of
resources  and the  evaluation  of  results  relative  to  employee  performance
compensation targets.  Investors should consider these non-GAAP measures only as
a  supplement  to,  not as a  substitute  for or as  superior  to,  measures  of
financial performance prepared in accordance with GAAP.

Safe-Harbor Statement
---------------------
This press release may contain  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange Act of 1934, as amended.  All statements made in this press
release,   other  than  statements  of  historical  fact,  are   forward-looking
statements.  Forward-looking  statements reflect management's current knowledge,
assumptions,  beliefs,  estimates,  and  expectations  and express  management's
current views of future performance,  results, and trends. The Company wishes to
caution readers that actual results might differ materially from those described
in the forward-looking  statements.  Forward-looking statements are subject to a
number  of risks and  uncertainties,  including  the  factors  discussed  in the
Company's  filings with the  Securities and Exchange  Commission  (including the
Company's  annual  report on Form 10-K for the year ended  December  31,  2002),
which could cause the Company's  actual results to materially  differ from those
described in the forward-looking statements.  Although the Company believes that
the forward-looking  statements are accurate, there can be no assurance that any
forward-looking statement will prove to be accurate. A forward-looking statement
should not be  regarded  as a  representation  by the  Company  that the results
described therein will be achieved. The Company wishes to caution readers not to
place  undue  reliance on any  forward-looking  statement.  The  forward-looking
statements are made as of the date of this press release. The Company assumes no
obligation to update any forward-looking statement after this date.

Wright  Medical  Group,  Inc. is a global  orthopaedic  medical  device  company
specializing in the design,  manufacture and marketing of  reconstructive  joint
devices and bio-orthopaedic materials. The Company has been in business for more
than fifty years and markets its  products in over 40 countries  worldwide.  For
more information about Wright Medical, visit our website at www.wmt.com.

                               --Tables Follow--
(Page 4 of 6)

                           Wright Medical Group, Inc.
                 Consolidated Condensed Statements of Operations
                      (in thousands, except per share data)
                                   (unaudited)
                                                        Three Months Ended
                                                  ---------------------------
                                                    March 31,      March 31,
                                                      2003           2002
                                                  ------------    ----------

Net sales                                            $ 58,622      $ 51,706
Cost of sales                                          15,540        14,758
                                                  ------------    ----------
       Gross profit                                    43,082        36,948

Operating Expenses:
    Selling, general and administrative                30,305        26,955
    Research and development                            3,535         2,561
    Amortization of intangible assets                     804           853
    Stock-based expense                                   409           440
    Arbitration settlement award                            -        (4,200)
    Acquired in-process research and
    development costs                                   4,558             -
                                                  ------------    ----------
       Total operating expenses                        39,611        26,609
                                                  ------------    ----------

       Income from operations                           3,471        10,339
Interest expense, net                                     266           434
Other (income) expense, net                              (30)            16
                                                  ------------    ----------
       Income before income taxes                       3,235         9,889
Provision for income taxes                              1,234         2,970
                                                  ------------    ----------
       Net income                                    $  2,001      $  6,919
                                                  ============    ==========

Net income per common share--basic                   $    .06      $    .23
                                                  ============    ==========
Net income per common share--diluted                 $    .06      $    .21
                                                  ============    ==========
Weighted-average number of common shares
outstanding-basic                                      32,715        29,833
                                                  ============    ==========
Weighted-average number of common shares
outstanding-diluted
                                                       34,059        32,229
                                                  ============    ==========

                           Wright Medical Group, Inc.
                      Consolidated Condensed Sales Analysis
                       (dollars in thousands - unaudited)

                                                      Three Months Ended
                                         ----------------------------------
                                          March 31,   March 31,      %
                                            2003        2002       change
                                         ---------- ----------- ----------
Geographic
--------------------------
Domestic                                   $35,080    $30,914       13.5%
International                               23,542     20,792       13.2%
                                         ---------- ----------- ----------
Total net sales                            $58,622    $51,706       13.4%
                                         ========== =========== ==========
Product Line
--------------------------
Knee products                              $19,664    $19,303        1.9%
Hip products                                17,690     14,240       24.2%
Extremity products                           7,430      6,695       11.0%
Bio-orthopaedic materials                   11,409      9,162       24.5%
Other                                        2,429      2,306        5.3%
                                         ---------- ----------- ----------
Total net sales                            $58,622    $51,706       13.4%
                                         ========== =========== ==========
(Page 5 of 6)

                           Wright Medical Group, Inc.
       Reconciliation of Income from Operations to Income from Operations,
                 As Adjusted (dollars in thousands - unaudited)

                                                        Three Months Ended
                                                  ----------------------------
                                                    March 31,       March 31,
                                                      2003             2002
                                                  ------------   -------------
Income from Operations, as reported                  $  3,471        $ 10,339
Add:  Acquired in-process research and
development costs                                       4,558               -
Less:  Arbitration settlement award                         -         (4,200)
                                                  ------------   -------------
Income from Operations, as adjusted                  $  8,029         $ 6,139
                                                  ============   =============

                           Wright Medical Group, Inc.
             Reconciliation of Net Income to Net Income, As Adjusted
                       (dollars in thousands - unaudited)

                                                         Three Months Ended
                                                     --------------------------
                                                       March 31,     March 31,
                                                         2003          2002
                                                     ------------   -----------

Net income, as reported:                                  $2,001       $ 6,919
Add:  Acquired in-process research and
development costs, net of tax                              2,819             -
Less:  Arbitration settlement award, net of tax                -        (2,604)
                                                     ------------   -----------
Net income, as adjusted:                                $  4,820       $ 4,315

Net income, as adjusted, per common share--basic        $    .15       $   .14
                                                     ============   ===========
Net income, as adjusted, per common
share--diluted                                          $    .14       $   .13
                                                     ============   ===========
Weighted-average number of common shares
outstanding-basic                                         32,715        29,833
                                                     ============   ===========
Weighted-average number of common shares
outstanding-diluted                                       34,059        32,229
                                                     ============   ===========

                           Wright Medical Group, Inc.
  Reconciliation of Net Income to Cash Earnings and Cash Earnings, As Adjusted
                       (dollars in thousands - unaudited)

                                                        Three Months Ended
                                                  ------------------------------
                                                      March 31,        March 31,
                                                        2003             2002
                                                    ------------    ------------

Net income, as reported                                 $2,001         $ 6,919
Add:  Stock-based expense                                  409             440
Add:  Amortization of intangible assets                    804             853
                                                    ------------    ------------
    Cash earnings                                        3,214           8,212
Add:  Acquired in-process research and
development costs, net of tax                            2,819               -
Less:  Arbitration settlement award, net of tax              -          (2,604)
                                                    ------------    ------------
Cash earnings, as adjusted                            $  6,033         $ 5,608
                                                    ============    ============
(Page 6 of 6)
                           Wright Medical Group, Inc.
                      Consolidated Condensed Balance Sheets
                      (in thousands, except per share data)

                                                      March 31,     December 31,
                                                        2003           2002
                                                   ------------     ------------

Assets:
Current Assets:
    Cash and cash equivalents                         $ 52,841       $   51,373
    Accounts receivable, net                            44,747           39,571
    Inventories                                         58,418           55,628
    Prepaid expenses and other current assets           22,676           25,042
                                                   ------------      ----------
         Total current assets                          178,682          171,614
                                                   ------------      ----------
Property, plant and equipment, net                      59,198           59,215
Intangible assets, net                                  29,288           26,908
Other assets                                            15,943           16,446
                                                   ------------      ----------
                                                      $283,111         $274,183
                                                   ============      ==========

Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
    Accounts payable                                     $ 10,149      $   9,878
    Accrued expenses and other current liabilities         34,820         29,878
    Current portion of long-term obligations                5,778          5,676
                                                      ------------    ----------
       Total current liabilities                           50,747         45,432
                                                      ------------    ----------
Long-term obligations                                      16,321         16,586
Other liabilities                                           6,679          7,166
                                                      ------------    ----------
       Total liabilities                                   73,747         69,184
                                                      ------------    ----------

Stockholders' equity (deficit)                            209,364        204,999
                                                      ------------    ----------
                                                       $  283,111     $  274,183
                                                      ============    ==========